Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Illustration of a DNA strand © Shutterstock/Kateryna Kon

In the paper, published in the journal Nature, researchers from the Patel Group, MRC Weatherall Institute of Molecular Medicine along with colleagues at the MRC Laboratory of Molecular Biology in Cambridge, and Hubrecht Institute in Utrecht, describe a mechanism by which our bodies recognise and respond to toxins and chemotherapy.

Clues to this process came from patients with a rare illness, Cockayne syndrome. Children with Cockayne syndrome develop debilitating symptoms including premature ageing, kidney and brain degeneration, and severe weight loss. The genetic cause of this syndrome, loss of a Cockayne syndrome gene, leaves sufferers unable to repair DNA damage. However, a mouse model of the disease mimicking the loss of a Cockayne gene was unable to recreate the disease profile seen in humans.

Read the full story on the MRC Weatherall Institute of Molecular Medicine website

Similar stories

Oxford University wins prestigious Queen’s Anniversary Prize

Her Majesty The Queen has approved the award of The Queen’s Anniversary Prizes to twenty-one higher and further education institutions, including Oxford University, in the most recent round of the independently reviewed scheme. This prestigious award is the highest national honour available to universities and FE colleges across the UK.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

One high altitude explorer acknowledges another

NASA Astronaut and Physiologist Dr Jessica Meir unveils The Physiological Society blue plaque in honour of fellow pioneering Physiologist and Scientific Explorer Mabel FitzGerald.